What question did this study set out to answer?

To investigate whether detecting minimal FLT3-ITD clones on day +30 post-HSCT can predict relapse risk in AML.

March 5, 2026Open Access

Day + 30 detection of minimal residual FLT3-ITD by high-sensitivity PCR-NGS predicts relapse risk and guides post-transplant maintenance in AML

Key Points

To investigate whether detecting minimal FLT3-ITD clones on day +30 post-HSCT can predict relapse risk in AML.
Conducted a study on AML patients post-HSCT
Utilized high-sensitivity PCR-NGS for detection of FLT3-ITD
Analyzed the association between FLT3-ITD detection and relapse risk
Detection of FLT3-ITD at day +30 reliably stratified patients' relapse risk
Provided a basis for individualized post-transplant maintenance therapy

Abstract

This is the first study to demonstrate that detection of minimal FLT3-ITD clones at the fixed time point of day + 30 post-HSCT can reliably stratify relapse risk in AML patients and provide a rationale for individualized post-transplant maintenance therapy.

Bookmark

View Full Paper